Pfizer, BioNTech start mid-phase trial for Omicron vaccine
American Pfizer Inc. and its German partner BioNTech SE announced on Wednesday that they initiated a "randomized, active-controlled, observer-blind" mid-stage vaccine trial for an unspecified Omicron variant of COVID-19.